Mucins in pancreatic cancer and its microenvironment

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 10, 2013, Pages 607-620

  Kaur, Sukhwinder ^a   Kumar, Sushil ^a   Momi, Navneet ^a   Sasson, Aaron R ^b   Batra, Surinder K ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 195 ANTIGEN; CA 242 ANTIGEN; CA 50 ANTIGEN; CLIVATUZUMAB TETRAXETAN Y 90; DUPAN 2; GO 201; MONOCLONAL ANTIBODY PAM4 I 131; MONOCLONAL ANTIBODY PAM4 TC 99M; MUCIN; MUCIN 1; MUCIN 16; MUCIN 2; MUCIN 4; MUCIN 5AC; MUCIN 7; OREGOVOMAB; PANKOMAB; PEPTIDE VACCINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL ADHESION; CELL POLARITY; CELLULAR DISTRIBUTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LUNG METASTASIS; MUCINOUS CYSTIC NEOPLASM; NEOPLASM; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; REVIEW; SOLID TUMOR; STROMA CELL; SURVIVAL TIME; TANDEM REPEAT; TUMOR MICROENVIRONMENT;

DISEASE PROGRESSION; EPITHELIAL CELLS; HUMANS; MUCINS; PANCREATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84885289630     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.120     Document Type: Review

References (154)

1. Cancer Facts and Statistics. American Cancer Society [online], http://www.cancer.org/research/cancerfactsstatistics/(2013).
2. Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874-885 (2009).
3. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60 (2004). (Pubitemid 38082153)
4. Pflugfelder, S. C. et al. Detection of sialomucin complex (MUC4) in human ocular surface epithelium and tear fluid. Invest. Ophthalmol. Vis. Sci. 41, 1316-1326 (2000). (Pubitemid 30261853)
5. Moniaux, N., Escande, F., Porchet, N., Aubert, J. P. & Batra, S. K. Structural organization and classification of the human mucin genes. Front. Biosci. 6, D1192-D1206 (2001).
6. Bafna, S., Kaur, S. & Batra, S. K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29, 2893-2904 (2010).
7. Senapati, S., Sharma, P., Bafna, S., Roy, H. K. & Batra, S. K. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer. Histol. Histopathol. 23, 1541-1552 (2008).
8. Singh, A. P. et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 9, 1076-1085 (2008).
9. Nagata, K. et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J. Hepatobiliary Pancreat. Surg. 14, 243-254 (2007). (Pubitemid 46863913)
10. Yonezawa, S., Higashi, M., Yamada, N., Yokoyama, S. & Goto, M. Significance of mucin expression in pancreatobiliary neoplasms. J. Hepatobiliary Pancreat. Sci. 17, 108-124 (2010).
11. Yonezawa, S. et al. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol. Int. 48, 319-322 (1998). (Pubitemid 28328315)
12. Swartz, M. J. et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol. 117, 791-796 (2002). (Pubitemid 34457016)
13. Saitou, M. et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J. Clin. Pathol. 58, 845-852 (2005). (Pubitemid 41113392)
14. Takikita, M. et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res. 69, 2950-2955 (2009).
15. Yamasaki, H. et al. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. Int. J. Oncol. 24, 107-113 (2004).
16. Moniaux, N., Junker, W. M., Singh, A. P., Jones, A. M. & Batra, S. K. Characterization of human mucin MUC17. Complete coding sequence and organization. J. Biol. Chem. 281, 23676-23685 (2006). (Pubitemid 44274143)
17. Haridas, D. et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE 6, e26839 (2011).
18. Chauhan, S. C. et al. MUC13 mucin augments pancreatic tumorigenesis. Mol. Cancer Ther. 11, 24-33 (2012).
19. Nissim, S., Idos, G. E. & Wu, B. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas 41, 1195-1205 (2012).
20. Shimamoto, T. et al. MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography. Pancreas 39, 879-883 (2010).
21. Maker, A. V. et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann. Surg. Oncol. 18, 199-206 (2011).
22. Choudhury, A. et al. Alternate splicing at the 3'-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratog. Carcinog. Mutagen. 21, 83-96 (2001).
23. Escande, F. et al. Genomic organization of MUC4 mucin gene. Towards the characterization of splice variants. Eur. J. Biochem. 269, 3637-3644 (2002). (Pubitemid 34989112)
24. Singh, P. K. & Hollingsworth, M. A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16, 467-476 (2006). (Pubitemid 44293402)
25. Singh, A. P., Moniaux, N., Chauhan, S. C., Meza, J. L. & Batra, S. K. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 64, 622-630 (2004). (Pubitemid 38120902)
26. Pochampalli, M. R., el Bejjani, R. M. & Schroeder, J. A. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 26, 1693-1701 (2007). (Pubitemid 46426203)
27. Pochampalli, M. R., Bitler, B. G. & Schroeder, J. A. Transforming growth factor dependent cancer progression is modulated by Muc1. Cancer Res. 67, 6591-6598 (2007). (Pubitemid 47105503)
28. Li, X., Wang, L., Nunes, D. P., Troxler, R. F. & Offner, G. D. Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor. Cancer Biol. Ther. 4, 968-973 (2005). (Pubitemid 41598592)
29. Hisatsune, A. et al. Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem. Biophys. Res. Commun. 405, 377-381 (2011).
30. Li, Y. et al. Heregulin targets ?-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol. Cancer Res. 1, 765-775 (2003). (Pubitemid 37025595)
31. Chaturvedi, P. et al. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 68, 2065-2070 (2008). (Pubitemid 351521776)
32. Funes, M., Miller, J. K., Lai, C., Carraway, K. L. & Sweeney, C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J. Biol. Chem. 281, 19310-19319 (2006). (Pubitemid 44035436)
33. Price-Schiavi, S. A. et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99, 783-791 (2002). (Pubitemid 34575694)
34. Chaturvedi, P. et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res. 5, 309-320 (2007). (Pubitemid 46706993)
35. Jonckheere, N. et al. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS ONE 7, e32232 (2012).
36. Gupta, B. K. et al. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J. Histochem. Cytochem. 60, 822-831 (2012).
37. Xu, H. et al. Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with ?-catenin in tumor progression. Life Sci. 88, 1063-1069 (2011).
38. Singh, P. K. et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J. Biol. Chem. 283, 26985-26995 (2008).
39. Lau, S. K. et al. EGFR-mediated carcinoma cell metastasis mediated by integrin ?v?5 depends on activation of c-Src and cleavage of MUC1. PLoS ONE 7, e36753 (2012).
40. Bitler, B. G., Goverdhan, A. & Schroeder, J. A. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J. Cell Sci. 123, 1716-1723 (2010).
41. Inaguma, S., Kasai, K. & Ikeda, H. GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. Oncogene 30, 714-723 (2011).
42. Kondo, A. et al. From glycomics to functional glycomics of sugar chains: Identification of target proteins with functional changes using gene targeting mice and knock down cells of FUT8 as examples. Biochim. Biophys. Acta 1764, 1881-1889 (2006). (Pubitemid 44895650)
43. Remmers, N. et al. Aberrant expression of mucin core proteins and O-linked glycans associated with progression of pancreatic cancer. Clin. Cancer Res. 19, 1981-1993 (2013).
44. Park, H. U. et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Lex antigen in pancreatic intraepithelial neoplasia. Pancreas 26, e48-e54 (2003).
45. Yue, T. et al. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol. Cell. Proteomics 8, 1697-1707 (2009).
46. Kui, W. N. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 278, 28619-28634 (2003).
47. Tu, L. & Banfield, D. K. Localization of Golgi-resident glycosyltransferases. Cell. Mol. Life Sci. 67, 29-41 (2010).
48. Colley, K. J. Golgi localization of glycosyltransferases: more questions than answers. Glycobiology 7, 1-13 (1997). (Pubitemid 27091315)
49. Varki, A. Selectin ligands. Proc. Natl Acad. Sci. USA 91, 7390-7397 (1994). (Pubitemid 24238190)
50. Yu, C. J. et al. Sialyl Lewis antigens: association with MUC5AC protein and correlation with post-operative recurrence of non-small cell lung cancer. Lung Cancer 47, 59-67 (2005).
51. Geng, Y., Marshall, J. R. & King, M. R. Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the circulation. Ann. Biomed. Eng. 40, 790-805 (2012).
52. Chen, S. H., Dallas, M. R., Balzer, E. M. & Konstantopoulos, K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J. 26, 1349-1359 (2012).
53. Komatsu, M., Yee, L. & Carraway, K. L. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res. 59, 2229-2236 (1999). (Pubitemid 29217690)
54. Komatsu, M., Tatum, L., Altman, N. H., Carothers Carraway, C. A. & Carraway, K. L. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int. J. Cancer. 87, 480-486 (2000). (Pubitemid 30639805)
55. Besmer, D. M. et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 71, 4432-4442 (2011).
56. Kohlgraf, K. G. et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 63, 5011-5020 (2003). (Pubitemid 37022639)
57. Tinder, T. L. et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J. Immunol. 181, 3116-3125 (2008).
58. Zhao, Q. et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 9, 154 (2010).
59. Sanders, W. J., Katsumoto, T. R., Bertozzi, C. R., Rosen, S. D. & Kiessling, L. L. L-selectin-carbohydrate interactions: relevant modifications of the Lewis x trisaccharide. Biochemistry 35, 14862-14867 (1996). (Pubitemid 26423820)
60. Cadron, I. et al. The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells. Gynecol. Oncol. 118, 64-68 (2010).
61. Agrawal, B., Gendler, S. J. & Longenecker, B. M. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol. Med. Today 4, 397-403 (1998). (Pubitemid 28411034)
62. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60 (2004). (Pubitemid 38082153)
63. Kleeff, J. et al. Pancreatic cancer microenvironment. Int. J. Cancer 121, 699-705 (2007). (Pubitemid 47106197)
64. Tsuboi, S. et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30, 3173-3185 (2011).
65. Senapati, S. et al. Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin. Cancer Res. 17, 267-274 (2011).
66. Gaida, M. M. et al. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Pathol. Oncol. Res. 18, 299-307 (2012).
67. Okamoto, T. et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol. Med. Report 7, 359-364 (2013).
68. Suzuki, Y. et al. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int. J. Oncol. 40, 1831-1838 (2012).
69. Swanson, B. J. et al. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67, 10222-10229 (2007). (Pubitemid 350070795)
70. Konowalchuk, J. D. & Agrawal, B. MUC1 is a novel costimulatory molecule of human T cells and functions in an AP-1-dependent manner. Hum. Immunol. 73, 448-455 (2012).
71. Ohno, S. et al. Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis. Anticancer Res. 26, 4047-4053 (2006). (Pubitemid 46031550)
72. Feig, C. et al. The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266-4276 (2012).
73. Nath, D. et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 98, 213-219 (1999). (Pubitemid 29487642)
74. Allavena, P. et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin. Dev. Immunol. 2010, 547179 (2010).
75. Kitamoto,S. et al. MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors, Oncogene http://dx.doi.org/10. 1038/onc.2012.478.
76. Chaika, N. V. et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 to regulate metabolism in pancreatic cancer. Proc. Natl Acad. Sci. USA 109, 13787-13792 (2012).
77. Tsutsumida, H. et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin. Cancer Res. 12, 2976-2987 (2006). (Pubitemid 43837341)
78. Sawada, T. et al. Biphasic effect of cell surface sialic acids on pancreatic cancer cell adhesiveness. Biochem. Biophys. Res. Commun. 195, 1096-1103 (1993). (Pubitemid 23280528)
79. Senapati, S., Gnanapragassam, V. S., Moniaux, N., Momi, N. & Batra, S. K. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene 31, 3346-5610 (2011).
80. Paszek, M. J., Boettiger, D., Weaver, V. M. & Hammer, D. A. Integrin clustering is driven by mechanical resistance from the glycocalyx and the substrate. PLoS Comput. Biol. 5, e1000604 (2009).
81. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906 (2009).
82. Wang, Y. et al. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int. J. Cancer. 121, 2716-2722 (2007). (Pubitemid 350136417)
83. Carrara, S. et al. Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies. Am. J. Gastroenterol. 106, 1359-1363 (2011).
84. Jhala, N. et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am. J. Clin. Pathol. 126, 572-579 (2006).
85. Horn, A. et al. Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology. Arch. Pathol. Lab. Med. 137, 546-551 (2013).
86. Tewes, M. et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 115, 581-590 (2009).
87. Kaur, S., Baine, M. J., Jain, M., Sasson, A. R. & Batra, S. K. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark. Med. 6, 597-612 (2012).
88. Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. Gastrointest. Oncol. 3, 105-119 (2012).
89. Goggins, M. Molecular markers of early pancreatic cancer. J. Clin. Oncol. 23, 4524-4531 (2005). (Pubitemid 46196582)
90. Goonetilleke, K. S. & Siriwardena, A. K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33, 266-270 (2007). (Pubitemid 46488663)
91. Yue, T. et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS ONE 6, e29180 (2011).
92. Shiozaki, K., Yamaguchi, K., Takahashi, K., Moriya, S. & Miyagi, T. Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. J. Biol. Chem. 286, 21052-21061 (2011).
93. Qiu, J. et al. Occurrence of autoantibodies to annexin I, 14-3-3 ? and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 26, 5060-5066 (2008).
94. Zhong, L. et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 1, 513-519 (2006). (Pubitemid 47181397)
95. Pedersen, J. W. et al. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br. J. Cancer 108, 107-114 (2013).
96. Pedersen, J. W. et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 128, 1860-1871 (2011).
97. Bafna, S., Kaur, S., Momi, N. & Batra, S. K. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer 101, 1155-1161 (2009).
98. Karanikas, V. et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997). (Pubitemid 28007547)
99. Ioannides, C. G. et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151, 3693-3703 (1993). (Pubitemid 23282681)
100. Rowse, G. J., Tempero, R. M., VanLith, M. L., Hollingsworth, M. A. & Gendler, S. J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58, 315-321 (1998). (Pubitemid 28047073)
101. Turner, M. S., Cohen, P. A. & Finn, O. J. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178, 2787-2793 (2007). (Pubitemid 46333156)
102. Tempero, R. M. et al. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161, 5500-5506 (1998). (Pubitemid 28519113)
103. Barratt-Boyes, S. M., Vlad, A. & Finn, O. J. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin. Cancer Res. 5, 1918-1924 (1999). (Pubitemid 29334476)
104. Soares, M. M., Mehta, V. & Finn, O. J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-6563 (2001). (Pubitemid 32467194)
105. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J. & Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298-304 (1996). (Pubitemid 26197209)
106. Ramanathan, R. K. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254-264 (2005). (Pubitemid 40174243)
107. Yamamoto, K. et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 25, 3575-3579 (2005). (Pubitemid 41105243)
108. Kaufman, H. L. et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 5, 60 (2007).
109. Kawaoka, T. et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol. Rep. 20, 155-163 (2008).
110. Kawaoka, T., Takashima, M., Yamamoto, K., Ueno, T. & Oka, M. Adoptive immunotherapy using MUC1-specific CTLs for unresectable pancreatic cancer [Japanese]. Nihon Rinsho 64 (Suppl. 1), 279-282 (2006).
111. Kondo, H. et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28, 379-387 (2008). (Pubitemid 351362841)
112. Wu, J. et al. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy. Immunopharmacol. Immunotoxicol. 31, 468-476 (2009).
113. Fan, X. N., Karsten, U., Goletz, S. & Cao, Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol. Res. Pract. 206, 585-589 (2010).
114. Berek, J. et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 27, 418-425 (2009).
115. Bitler, B. G. et al. Intracellular MUC1 peptides inhibit cancer progression. Clin. Cancer Res. 15, 100-109 (2009).
116. Raina, D. et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 69, 5133-5141 (2009).
117. Savla, R., Taratula, O., Garbuzenko, O. & Minko, T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control Release 153, 16-22 (2011).
118. Andrianifahanana, M. et al. MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am. J. Gastroenterol. 101, 2319-2329 (2006). (Pubitemid 44477560)
119. Ren, J. et al. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol. Cancer Res. 4, 873-883 (2006). (Pubitemid 44877017)
120. Choudhury, A. et al. Retinoic acid-dependent transforming growth factor 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor signaling pathway. J. Biol. Chem. 275, 33929-33936 (2000).
121. Strobel, O. et al. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology 138, 1166-1177 (2010).
122. Colomb, F. et al. TNF regulates sialyl-Lewisx and 6-sulfo-sialyl-Lewisx expression in human lung through up-regulation of ST3GAL4 transcript isoform BX. Biochimie 94, 2045-2053 (2012).
123. Springer, G. F. T and Tn, general carcinoma autoantigens. Science 224, 1198-1206 (1984). (Pubitemid 14109457)
124. Nanashima, A. et al. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas. J. Hepatobiliary Pancreat. Surg. 6, 391-395 (1999).
125. Yu, L. G. et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 282, 773-781 (2007).
126. Tsuboi, S. Hatakeyama, S., Ohyama, C. & Fukuda, M. Two opposing roles of O-glycans in tumor metastasis. Trends Mol. Med. 18, 224-232 (2012).
127. Lee, S. H. et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of ?2?1 integrin complex. J. Biol. Chem. 284, 17157-17169 (2009).
128. Terris, B. et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J. Pathol. 197, 632-637 (2002).
129. Yonezawa, S. et al. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. Hum. Pathol. 28, 344-352 (1997). (Pubitemid 27106088)
130. Yonezawa, S. et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol. Int. 49, 45-54 (1999). (Pubitemid 29421947)
131. Andrianifahanana, M. et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res. 7, 4033-4040 (2001). (Pubitemid 34044624)
132. Shimizu, A. et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103, 739-746 (2012).
133. Higuchi, T. et al. Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J. Biol. Chem. 279, 1968-1979 (2004). (Pubitemid 38084468)
134. Itoh, Y. et al. Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin. Glycobiology 18, 74-83 (2008).
135. Rückert, F., Pilarsky, C. & Grützmann, R. Serum tumor markers in pancreatic cancer-recent discoveries. Cancer 2, 1107 (2010).
136. Ni, X. G. et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur. J. Surg. Oncol. 31, 164-169 (2005). (Pubitemid 40214752)
137. Tsutsumi, K. et al. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology 12, 409-416 (2012).
138. Bunger, S., Laubert, T., Roblick, U. J. & Habermann, J. K. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J. Cancer Res. Clin. Oncol. 137, 375-389 (2011).
139. Yonezawa, S., Higashi, M., Yamada, N. & Goto, M. Precursor lesions of pancreatic cancer. Gut Liver 2, 137-154 (2008).
140. Gold, D. V. et al. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 119, 522-528 (2013).
141. Lepisto, A. J. et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6, 955-964 (2008).
142. Pecher, G., Haring, A., Kaiser, L. & Thiel, E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol. Immunother. 51, 669-673 (2002). (Pubitemid 35446294)
143. Gulec, S. A. et al. Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: a phase I single-dose escalation trial, Clin. Cancer Res. 17, 4091-4100 (2011).
144. Cardillo, T. M., Ying, Z. & Gold, D. V. Therapeutic advantage of 90yttrium versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin. Cancer Res. 7, 3186-3192 (2001). (Pubitemid 32963842)
145. Gold, D. V., Cardillo, T., Vardi, Y. & Blumenthal, R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int. J. Cancer 71, 660-667 (1997). (Pubitemid 27239379)
146. Gold, D. V., Cardillo, T., Goldenberg, D. M. & Sharkey, R. M. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit. Rev. Oncol. Hematol. 39, 147-154 (2001). (Pubitemid 32551996)
147. Joshi, M. D. et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol. Cancer Ther. 8, 3056-3065 (2009).
148. Brockhausen, I., Schachter, H. & Stanley, P. in Essentials of Glycobiology. 2nd edn Ch. 9 (Cold Spring Harbor, 2009).
149. Lang, T., Hansson, G. C. & Samuelsson, T. Gel-forming mucins appeared early in metazoan evolution. Proc. Natl Acad. Sci. USA 104, 16209-16214 (2007). (Pubitemid 350099386)
150. Chaturvedi, P., Singh, A. P. & Batra, S. K. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 22, 966-981 (2008). (Pubitemid 351519954)
151. Duraisamy, S., Ramasamy, S., Kharbanda, S. & Kufe, D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene 373, 28-34 (2006).
152. Pelaseyed, T. et al. Unfolding dynamics of the mucin SEA domain probed by force spectroscopy suggest that it acts as a cell protective device. FEBS J. 280, 1491-1501 (2013).
153. Ho, S. B. et al. Activity of recombinant cysteine-rich domain proteins derived from the membrane-bound MUC17/Muc3 family mucins. Biochim. Biophys. Acta 1800, 629-638 (2010).
154. Ciccarelli, F. D., Doerks, T. & Bork, P. AMOP, a protein module alternatively spliced in cancer cells. Trends Biochem. Sci. 27, 113-115 (2002). (Pubitemid 34219315)